Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    -1.00 (-1.37%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £337.35m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Nov 20198:41 amRNSDirector/PDMR Shareholding
13th Nov 20197:00 amRNSLG Chem Life Sciences Expands Partnership
11th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20196:30 pmRNSHolding(s) in Company
8th Nov 20196:26 pmRNSHolding(s) in Company
7th Nov 20191:00 pmRNSHolding(s) in Company
7th Nov 201911:00 amRNSHolding(s) in Company
6th Nov 20192:30 pmRNSHolding(s) in Company
4th Nov 20191:18 pmRNSResult of General Meeting
18th Oct 201912:06 pmRNSProposed Placing & Subscription to raise up to £9M
18th Oct 201912:05 pmRNSInterim Results for the Period Ended 31 July 2019
10th Oct 20197:00 amRNSCollaboration with ADC Therapeutics
5th Aug 20199:05 amRNSSecond Price Monitoring Extn
5th Aug 20199:00 amRNSPrice Monitoring Extension
29th Jul 20197:00 amRNSAvacta's CEO to Present at Biotech Investor Day
20th Jun 20197:00 amRNSAvacta and Selexis Partner to Develop Cell Line
19th Jun 20197:00 amRNSTurner Pope Investor Evening
12th Jun 20197:00 amRNSAvacta's CSO to Present at Major US Conference
10th Jun 20197:00 amRNSAvacta hits Clinical Candidate Selection Milestone
3rd Jun 20197:00 amRNSTMAC Programme Accelerates
23rd Apr 20193:48 pmRNSIssue of Equity
12th Apr 20192:46 pmRNSHolding(s) in Company
9th Apr 20197:00 amRNSInterim Results
8th Mar 201912:14 pmRNSIssue of Equity
6th Feb 201912:27 pmEQSHardman & Co Research: Avacta (AVCT): A second wake-up call for the market
4th Feb 20197:00 amRNSModerna Exercises Exclusive Product License Option
28th Jan 20197:00 amRNSDirector Appointment
21st Jan 20193:40 pmRNSResult of Annual General Meeting
21st Jan 20197:00 amRNSAGM Business Update and Notice of Results
18th Jan 20195:08 pmRNSShare Incentive Plan/Issue of Equity
9th Jan 201911:06 amRNSHolding(s) in Company
7th Jan 20192:50 pmRNSDirector/PDMR Shareholdings
3rd Jan 20198:56 amRNSHolding(s) in Company
2nd Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20181:41 pmRNSHolding(s) in Company
19th Dec 20183:32 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSAvacta London Science Day
12th Dec 201812:50 pmRNSHolding(s) in Company
12th Dec 201812:44 pmRNSHolding(s) in Company
12th Dec 20187:00 amRNSAppointment of Chief Medical Officer
11th Dec 20187:00 amRNSPosting of Annual Report and Notice of AGM
10th Dec 20182:05 pmRNSSecond Price Monitoring Extn
10th Dec 20182:00 pmRNSPrice Monitoring Extension
10th Dec 20187:30 amEQSHardman & Co Research: Avacta (AVCT): Wake-up call for the market
10th Dec 20187:00 amRNSDevelopment Partnership with LG Chem Life Sciences
12th Nov 20187:00 amRNSAvacta to Present at Major European Conference
11th Oct 20187:00 amRNSAvacta's CTO to Present at Major US Conference
10th Oct 20187:00 amRNSAvacta agrees Affimer reagent licensing deal
2nd Oct 20187:00 amRNSPreliminary Results
21st Sep 20187:00 amRNSInvestor Meeting and Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.